Diabetes technology & therapeutics最新文献

{"title":"Accuracy of Dexcom G6® and FreeStyle Libre® Sensors in Standardized Hypoxia Conditions: A Randomized Controlled Trial-FOX Study.","authors":"Nathanaël Bassas Letissier, Christophe Rault, Corentin Faucher, Emilie Rabois, Lisa Durocher, Claire Bouleti, Stéphanie Ragot, Samy Hadjadj, Helena Mosbah, Xavier Piguel, Benjamin Alos, Raphaël Thuillier, Pierre-Jean Saulnier","doi":"10.1177/15209156261423954","DOIUrl":"10.1177/15209156261423954","url":null,"abstract":"<p><strong>Background: </strong>Continuous glucose monitoring (CGM) systems predominantly rely on oxygen-dependent enzymatic electrochemistry. While their accuracy is well established in normoxic conditions, little evidence exists regarding their performance during hypoxia, a situation encountered during altitude exposure, air travel, or specific medical conditions. This study assessed the accuracy of two widely used glucose-oxidase CGM systems (FreeStyle Libre® and Dexcom G6®) during controlled hypoxia.</p><p><strong>Methods: </strong>In a randomized controlled study, healthy volunteers and participants with diabetes were exposed to standardized normobaric hypoxia (fraction of inspired oxygen of 14.5%). Participants simultaneously wore FreeStyle and Dexcom sensors. Venous plasma glucose, analyzed using the hexokinase method, served as the reference. To induce glycemic excursions, participants consumed a standardized mixed meal and performed moderate-intensity cycling exercise. The primary end point was the mean absolute relative difference (MARD) comparing CGM values with reference glucose. Secondary assessments included consensus error grid analysis (CEGA).</p><p><strong>Results: </strong>Thirty participants were included (15 healthy volunteers and 15 with diabetes). Median age was 29.5 (interquartile range [IQR]: 23.0-41.0) years, and median body mass index was 23.3 (IQR, 22.0-26.4) kg/m². Among participants with diabetes, 53% had type 1 diabetes and 47% type 2, with a median diabetes duration of 16.3 [IQR, 11.3-21.6] years and HbA1c of 7.5% [IQR, 6.6-7.8]. During hypoxia MARD values were 21.2% for FreeStyle and 41.8% for Dexcom in healthy volunteers and 11.8% and 17.5%, respectively, in participants with diabetes. CEGA showed that 97% of FreeStyle and 87% of Dexcom readings fell within zones A or B during hypoxia.</p><p><strong>Conclusions: </strong>Both CGM systems showed reduced accuracy under hypoxia, particularly during dynamic glycemic changes. Awareness of these limitations and selective confirmation with capillary testing can assist safe use when clinically relevant decisions are required. The implications for automated insulin delivery systems warrant further dedicated evaluation.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"969-979"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of a Continuous Glucose Monitor in the Intensive Care Unit.","authors":"Eric Cucchi, Asem Ali, Yurima Guilarte-Walker, Bruce Barton, Samir Malkani, John Mordes","doi":"10.1177/15209156261423933","DOIUrl":"10.1177/15209156261423933","url":null,"abstract":"<p><strong>Objectives: </strong>Continuous glucose monitoring (CGM) devices are routinely used in the outpatient management of diabetes. They are not yet approved for use in intensive care units (ICUs). The main objective of this study was to determine the accuracy of CGM glucose determinations made in an ICU by comparing them with standard glucose measurements obtained during routine care. Secondary objectives were to determine the frequency of device malfunctions or adverse events and to assess acceptance of CGM use by caregivers.</p><p><strong>Methods: </strong>Dexcom™ G7 CGM sensors were placed on non-randomized, consented ICU patients with known hyperglycemia. CGM glucose concentrations were recorded in a Dexcom Clarity™ database and compared with near-simultaneous (±5 min) measurements obtained by laboratory or point-of-care measurements recorded in an electronic medical record. Determinations of accuracy were made using a Clarke Error Grid plot and by calculating mean absolute relative difference (MARD). Device failure and adverse event data were recorded in the electronic record. Caregiver acceptance was assessed by interview.</p><p><strong>Results: </strong>During a 9-month period, 16 subjects were enrolled after obtaining informed consent. The median duration of CGM use on subjects was 5.5 (range 1-20) days. A total of 941 near-simultaneous CGM and routine care data were collected. Clarke Error Grid comparison of CGM and routine care data showed 99.7% of readings in regions A or B and 0.3% in other regions. The MARD of all readings was 12.25%. There were no adverse events attributable to the CGM recorded. Qualitative analysis of nursing responses revealed no concerns regarding the addition of CGM to the routine workflow.</p><p><strong>Conclusion: </strong>CGM glucose readings in the ICU may be reliable to use in certain critically ill patient populations. CGM may not be reliable in patients requiring high-dose vasopressors. The use of CGM to enhance patient care in ICUs merits additional research.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"916-923"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended Use of Automated Insulin Delivery in Young People with Type 1 Diabetes and Elevated HbA1c: 52-Week Outcomes of the CO-PILOT Trial.","authors":"Marcus C Ward, Alisa Boucsein, Yongwen Zhou, Venus R Michaels, Jillian J Haszard, Craig A Jefferies, Esko J Wiltshire, Ryan G Paul, Caleb A Lopez-Sanchez, Martin I de Bock, Benjamin J Wheeler","doi":"10.1177/15209156261426883","DOIUrl":"10.1177/15209156261426883","url":null,"abstract":"<p><strong>Aims: </strong>To assess longer term outcomes of automated insulin delivery (AID) in young people (7-25 years) with type 1 diabetes (T1D) and baseline glycated hemoglobin (HbA1c) ≥ 69 mmol/mol (8.5%).</p><p><strong>Methods: </strong>This 52-week, multicenter trial followed 74 participants through an initial 13-week randomized controlled trial comparing AID (MiniMed™ 780G [MM780G]) with standard care (multiple daily injections or continuous subcutaneous insulin infusion) and a 39-week continuation phase where all participants used AID. Due to differing AID exposure times, pooled data are presented for 39 weeks, with 52-week data reflecting extended follow-up for the \"AID first\" group. Outcomes included HbA1c, continuous glucose monitoring metrics, safety, system performance, and psychosocial measures.</p><p><strong>Results: </strong>Baseline mean (± standard deviation) HbA1c for all participants (<i>n</i> = 74) was 92 ± 20 mmol/mol (10.5 ± 1.9%). At 52 weeks, the mean HbA1c for the \"AID first\" group (<i>n</i> = 34) was 67 ± 18 mmol/mol (8.3 ± 1.6%), consistent with the 39-week value for all participants (67 ± 12 mmol/mol [8.3 ± 1.1%]). This followed an initial rapid decrease (mean change: -28 [95% confidence interval (CI): -33, -23] mmol/mol or -2.5 [95% CI: -3.0, -2.1] percentage points at 13 weeks post-AID) and stabilized from 26 weeks in the whole sample. Baseline mean time in range (TIR; 3.9-10 mmol/L) for all available participants (<i>n</i> = 68) was 23.1 ± 13.4%. Following substantial improvement and stabilization with AID use, the mean TIR for the \"AID first\" group (<i>n</i> = 32) was 63.1 ± 13.7% at 52 weeks. Compared with the 52 weeks before the trial, the diabetic ketoacidosis rate decreased substantially (mean difference: -35.7 events per 100 participant-years), and no severe hypoglycemia occurred. Improved treatment satisfaction and reduced fear of hypoglycemia were reported at 52 weeks.</p><p><strong>Conclusion: </strong>In young people with T1D and markedly elevated glycemia, longer term AID use with MM780G provided substantial, sustained improvements in glycemia without compromising safety. These findings support broader AID adoption in this high-risk population (Australian New Zealand Clinical Trials Registry number ACTRN12622001454763).</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"980-991"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Hypoglycemia Assessed by Continuous Glucose Monitoring: A Proposal to Define the End of a Hypoglycemic Event More Precisely.","authors":"Douglas B Muchmore, Peter Calhoun, Lutz Heinemann","doi":"10.1177/15209156261423957","DOIUrl":"10.1177/15209156261423957","url":null,"abstract":"","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"1001-1002"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycemic Outcomes During Outpatient Use of Automated Insulin Delivery Without Meal Announcement in Adults with Type 1 Diabetes: Results from the CLOSE IT Randomized Controlled Trial.","authors":"Tom Wilkinson, Natalie Nanayakkara, David Burren, Alicia Jenkins, Jonathan Williman, Celeste Keesing, Erin Boyle, Yasser Elghattis, Alison Bennett, Tim Gunn, Martin de Bock, Neale D Cohen","doi":"10.1177/15209156261423558","DOIUrl":"10.1177/15209156261423558","url":null,"abstract":"<p><strong>Introduction: </strong>Current automated insulin delivery (AID) systems recommend manual insulin delivery prior to meals (hybrid closed-loop [HCL]). Data are needed on the efficacy of an AID system without meal announcement.</p><p><strong>Materials and methods: </strong>In this randomized, open-label, parallel-arm trial, we established participants with type 1 diabetes aged 18-70 years on an open-source AID system, with meal announcement, during a 12-week run-in phase, followed by a 12-week trial phase with assignment in a 1:1 ratio to AID without meal announcement or HCL (continued meal announcement). The primary outcome was the percentage of time in the target glucose range of 70-180 mg/dL (3.9-10.0 mmol/L) in the final 14 days of the trial phase, adjusted for the same metric in the final 14 days of the run-in phase.</p><p><strong>Results: </strong>In total, 73 participants underwent randomization (36 to AID without meal announcement and 37 to HCL). Mean (±standard deviation) time in the target range at the end of the run-in and trial phases was 69 ± 11% and 66 ± 8% in the AID without meal announcement and 70 ± 9% and 69 ± 13% in the HCL group (adjusted difference, -2.2 percentage points; 95% confidence interval: -6.2 to 1.7).</p><p><strong>Conclusions: </strong>In adults with type 1 diabetes, use of an open-source AID system without meal announcement demonstrated glycemic efficacy and achieved a similar time in the target glucose range to use of the same system as HCL.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"941-950"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Dual Glucose-Ketone Monitoring as a Pump/AID Sick-Day Prevention Standard for Diabetic Ketoacidosis.","authors":"Dured Dardari","doi":"10.1177/15209156261423932","DOIUrl":"10.1177/15209156261423932","url":null,"abstract":"","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"999-1000"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Continuous Glucose Monitor on Health Care Resource Utilization in Adults with Type 2 Diabetes Managed by Noninsulin Therapies.","authors":"Anup K Sharma, Abraham Lee, Shivani Mehta, Qaashif Panjwani, Bhavya Sree Burugapalli","doi":"10.1177/15209156261423934","DOIUrl":"10.1177/15209156261423934","url":null,"abstract":"<p><strong>Background: </strong>Daily use of continuous glucose monitoring (CGM) has been shown to reduce diabetes-related events and associated costs in individuals with type 2 diabetes (T2D) regardless of their therapy. However, adoption of CGM among the large majority of T2D adults in the United States who are treated with noninsulin therapies has been limited.</p><p><strong>Methods: </strong>This retrospective database study assessed the effects of CGM acquisition on health care resource utilization (HCRU) in a large cohort of T2D adults treated with noninsulin, antidiabetes therapies. Inclusion criteria were T2D diagnosis, age ≥18 years, treated with noninsulin therapies, CGM-naive before CGM acquisition, and continuous medical/pharmacy insurance coverage during the 12-month preindex and postindex periods. The primary outcome measures were changes in all-cause hospitalizations (ACH), emergency department (ED) visits, acute diabetes complications, hyperglycemic events (HGE), and diabetic ketoacidosis (DKA) during the 12 months following CGM acquisition.</p><p><strong>Results: </strong>A total of 20,468 adults with T2D were included in this analysis. CGM acquisition was associated with significant reductions in event rates in the postindex period compared with the preindex period HCRU at 12 months: ACH (-25%), ED visits (-7%), HGE (-7%), DKA (-86%), and acute diabetes complications (-7%), all <i>P</i> < 0.0001. Similar reductions in events per person were also observed: ACH (-20.6%), ED visits (-7.2%), HGE (-6.2%), DKA (-63.0%), and acute diabetes complications (-6%), all <i>P</i> < 0.0001. Significant reductions were also seen in patients with cardiovascular disease. ACH and ED visits decreased by 35% and 12%, respectively; in those with liver disease by 25% and 13%; in those with renal disease, ACH decreased by 33%; and in those with hypertension, ACH and ED visits decreased by 26% and 7%, respectively. All reductions were statistically significant (<i>P</i> < 0.01).</p><p><strong>Conclusions: </strong>This analysis demonstrated an association between CGM acquisition and reductions in HCRU in adults with T2D treated with noninsulin therapies.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"951-957"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of Real-Time Continuous Glucose Monitoring System in Hospitalized Patients with Diabetes and Chronic Kidney Disease.","authors":"Yoshinori Kakutani, Tomoaki Morioka, Shoko Miyamoto, Yuka Natsuki, Yuya Miki, Akinobu Ochi, Masanori Emoto","doi":"10.1177/15209156261423902","DOIUrl":"10.1177/15209156261423902","url":null,"abstract":"<p><strong>Objective: </strong>Real-time continuous glucose monitoring (CGM) systems are beneficial for patients with diabetes by providing a comprehensive assessment of glycemic status and reducing hypoglycemia. However, their performance in patients with both diabetes and chronic kidney disease (CKD) during hospitalization remains unclear. This study aimed to evaluate the accuracy of real-time CGM in hospitalized patients with diabetes and CKD.</p><p><strong>Research design and methods: </strong>We conducted a prospective observational study including 52 patients with diabetes after excluding those with acute kidney injury, active glomerulonephritis, requiring intensive care, or undergoing hemodialysis. Participants were categorized by estimated glomerular filtration rate (eGFR, mL/min/1.73 m²) into G1-2 (≥60), G3 (30-59), and G4-5 (<30). Capillary glucose values were measured with a validated point-of-care (POC) device and paired with corresponding real-time CGM (G6, Dexcom) readings. Accuracy was assessed by mean absolute relative difference (MARD), correlation analyses, Bland-Altman plots, and consensus error grid (CEG) analyses.</p><p><strong>Results: </strong>A total of 1603 paired glucose values were analyzed, including 752 in G1/2, 571 in G3, and 280 in G4/5. CGM and POC glucose were strongly correlated (<i>r</i> = 0.91, <i>P</i> < 0.001). The overall MARD was 17.0%, with group-specific values of 19.4% in G1/2, 15.5% in G3, and 13.5% in G4/5 (<i>P</i> < 0.001). Bland-Altman plots showed smaller bias and narrower limits of agreement in advanced CKD. CEG analyses demonstrated high agreement, with >99% of values within clinically acceptable zones.</p><p><strong>Conclusions: </strong>The Dexcom G6 demonstrated reliable accuracy in hospitalized patients with diabetes and CKD, with better performance in advanced CKD. These findings support its clinical utility in this population.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"958-968"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146200567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous Ketone Monitoring in Diabetic Ketoacidosis: Prospective Multicenter Method-Comparison and Feasibility Study.","authors":"Nathan L Haas, Frederick K Korley, Ryan M Schneider, Sai Likhita Mamillapalli, Emily Hepworth, James A Cranford, Yu Kuei Lin, Richard T Griffey","doi":"10.1177/15209156261428034","DOIUrl":"10.1177/15209156261428034","url":null,"abstract":"<p><strong>Introduction: </strong>Continuous ketone monitoring (CKM) could optimize diabetic ketoacidosis (DKA) treatment by monitoring beta-hydroxybutyrate (BOHB) continuously and minimally invasively. However, data on the agreement between interstitial and venous BOHB during DKA is lacking. Our objectives were to assess the feasibility of CKM during DKA and the agreement between interstitial and venous BOHB.</p><p><strong>Methods: </strong>This was a prospective multicenter method-comparison study conducted at two U.S. emergency departments. Adults (>18 years) in DKA were included. BOHB was measured via SiBio CKM and compared with simultaneously collected venous BOHB every 2 h during DKA treatment. Following DKA resolution, study staff removed CKM and assessed for complications. The primary outcome was level of agreement via Bland-Altman analysis between simultaneously collected CKM and venous BOHB values. Additional outcomes included correlation (<i>r</i>) between concurrent CKM and venous BOHB values, first detection of DKA resolution, and feasibility (uncomplicated application and removal of CKM).</p><p><strong>Results: </strong>Thirty-four patients were enrolled, with a mean age of 40.8 years, 56% male, 50% Black, 79% type I diabetes, and mean presenting BOHB 7.0 mmol/L (range 2.5-13.5). We analyzed 164 paired CKM and venous BOHB values (mean [standard deviation (SD)] paired values per patient: 4.8 [3.8], range 1-16). Bland-Altman analysis found the average difference between CKM and venous BOHB was -0.38 mmol/L (95% confidence interval [CI] -1.63, 0.88). CKM values were strongly correlated with venous BOHB (<i>r</i> = 0.96, <i>p</i> < 0.001). The CKM value was lower than venous for 79% of paired values. DKA resolution was detected 55 min earlier (mean, 95% CI 26-84, <i>p</i> = 0.001) via CKM than standard care. No device-related complications occurred, and CKM application and removal were well tolerated by all patients.</p><p><strong>Conclusion: </strong>CKM during DKA treatment was feasible, provided clinically accurate BOHB readings, and detected DKA resolution earlier than standard care. CKM-guided DKA treatment is a promising strategy with the potential to improve the quality and value of DKA care.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"992-998"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intermittently Scanned Continuous Glucose Monitoring Enhances Weight Loss and Adherence in Women with Obesity: A Randomized Controlled Trial.","authors":"Marina Gradiser, Ines Bilic-Curcic, Ines Okun, Goran Toplek, Silvija Canecki Varzic, Vjekoslav Cigrovski, Lana Ruzic, Maja Cigrovski Berkovic","doi":"10.1177/15209156261423952","DOIUrl":"10.1177/15209156261423952","url":null,"abstract":"<p><strong>Background: </strong>Lifestyle interventions focusing on diet and physical activity often fail to achieve sustained weight loss, primarily due to low adherence. Intermittently scanned continuous glucose monitoring (isCGM) may serve as a behavioral feedback tool, enhancing motivation and compliance in individuals with obesity.</p><p><strong>Objectives: </strong>To evaluate whether incorporating isCGM into a structured lifestyle intervention improves weight loss, body composition, and metabolic outcomes in women living with obesity.</p><p><strong>Methods: </strong>In this 12-week randomized controlled trial, 35 women with overweight or obesity (body mass index [BMI] > 25 kg/m²) were assigned to either an intervention group (<i>n</i> = 17) using isCGM at baseline, mid-intervention, and study end, or a control group (<i>n</i> = 18) using isCGM only at baseline and end. Both groups participated in supervised exercise (3 sessions/week) and received identical dietary counseling. Primary outcomes included changes in body weight and BMI; secondary outcomes comprised body composition, adherence to dietary recommendations, and CGM metrics (time in range [TIR], time below range [TBR], coefficient of variation, HbA1c).</p><p><strong>Results: </strong>Compared with controls, the intervention group achieved significantly greater reductions in body weight (-5.5 ± 2.3 kg vs. -0.2 ± 1.8 kg, <i>P</i> < 0.001), BMI (-1.9 ± 0.6 vs. -0.1 ± 0.4 kg/m², <i>P</i> < 0.001), waist-to-height ratio, body fat, and visceral fat, alongside increased muscle mass and improved dietary adherence (<i>P</i> < 0.05). Clinically meaningful weight loss (≥3% BMI and body fat reduction) occurred in 35% of the intervention group versus 0% of controls. TIR improved modestly in the intervention group (<i>P</i> = 0.03).</p><p><strong>Conclusions: </strong>Integrating isCGM into lifestyle interventions enhances adherence and supports clinically significant improvements in body composition and glycemic control among women with obesity. Larger, longer-term studies are warranted to confirm these findings.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"907-915"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}